International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting
The new abstract titled, "3D Telomere Profiling of MRD (Minimal Residual Disease) in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression," will be presented at the meeting by Dr. Yulia Shifrin, Laboratory Director of Telo Genomics and published in Clinical Lymphoma, Myeloma & Leukemia. The abstract entails a technical methodology of MRD assessment based on TeloView profiling. Details of the abstract will be provided after the poster session.
TeloView MM-MRD's proprietary approach of counting and profiling individual MRD cells has the potential to provide actionable information on risk of relapse to clinicians.
The International Myeloma Society (IMS) is a global professional organization dedicated to advancing the science and treatment of multiple myeloma. Its upcoming 22nd Annual Meeting, will take place from September 17-20, 2025. IMS meetings are widely considered as a defining annual forum in the myeloma field.
"We are excited to share the next clinical application of our 3D telomere application for MRD for multiple myeloma at IMS," said Dr. Sabine Mai, Telo's Co-Founder. "The acceptance is a result of our commitment to develop a clinical offering and a novel approach of liquid biopsy MRD."
The Company announces that, further to its news release dated February 27, 2025, the Company has issued an aggregate of 411,539 common shares ("Shares") to Trusted Health Advisors LLC ("THA"), to compensate THA for its provision of services related to the partnering and commercialization of Telo's diagnostic technologies from January to July 1, 2025. Pursuant to the agreement between THA and the Company, 214,605 Shares were issued at a deemed price of $0.12 per Share, and 196,934 Shares were issued at a deemed price of $0.125 per Share, for total consideration of approximately $50,369, or US$36,000. All Shares are subject to a four-month hold period expiring November 11, 2025, in accordance with applicable securities law and TSX-V policies. In addition, the Shares issued at $0.12 per Share are subject to a voluntary resale restriction expiring March 31, 2026, and the Shares issued at $0.125 per Share are subject to a voluntary resale restriction expiring June 30, 2026.
About MRD Assessment
Minimal Residual Disease ("MRD") is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells, between being in remission or active, provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals in multiple myeloma.
MRD testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023).
About Multiple Myeloma
Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:Guido BaechlerExecutive Chairman647-477-9365info@telodx.comMaRS Centre, South Tower101 College Street, Suite 200Toronto, ON, M5G 1L7www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259811
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
5 hours ago
- Bloomberg
Tata Sons Expects Reprieve From Forced IPO Amid Regulator Review
Tata Sons Pvt., the closely-held holding company of India's salt-to-software conglomerate, is not making any preparations for a near-term share sale as it believes the country's regulators will extend a deadline to take itself public, said people familiar with the matter. Following engagement with officials, the company's leaders expect it will receive official communication from the Reserve Bank of India granting extension for an initial share sale amid a nationwide review of rules governing entities that are not public-facing and do not require public funds, said the people, who asked not to be named discussing information that's sensitive.
Miami Herald
16 hours ago
- Miami Herald
GameSquare Regains Compliance with Nasdaq's Minimum Bid Price Requirement
FRISCO, TX / ACCESS Newswire / July 25, 2025 / GameSquare Holdings, Inc. (NASDAQ:GAME) today announced that it received formal written confirmation from The Nasdaq Stock Market, LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq's minimum bid price requirement. To regain compliance with the Minimum Bid Price Requirement, the Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The closing bid price of the shares has been at $1.00 per share or greater for 10 consecutive business days from July 8 to July 21, 2025. Accordingly, Nasdaq Listing Qualifications Staff has notified the Company that it has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed. About GameSquare Holdings, Inc. GameSquare (NASDAQ: GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. Complementing our operating strategy, GameSquare operates a blockchain-native Ethereum treasury management program designed to generate onchain yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation. To learn more, visit Forward-Looking Statements: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company's future performance, revenue, growth and profitability; and the Company's ability to execute on its current and future business plans. These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company's ability to grow its business and being able to execute on its business plans, the success of Company's vendors and partners in their provision of services to the Company, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to supports its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company's ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company's portfolio across entertainment and media platforms, dependence on the Company's key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company's most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. GameSquare Corporate Contact Lou Schwartz, PresidentPhone: (216) 464-6400Email: ir@ GameSquare Investor Relations Andrew BergerPhone: (216) 464-6400Email: ir@ GameSquare Media Relations Chelsey Northern / The UntoldPhone: (254) 855-4028Email: pr@ SOURCE: GameSquare Holdings, Inc.
Yahoo
a day ago
- Yahoo
Rising Fiscal Deficits Drive Billions Into Credit
(Bloomberg) -- Investors are showing signs of pulling money out of government bonds and plowing it into US and European company debt. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US The High Costs of Trump's 'Big Beautiful' New Car Loan Deduction Can This Bridge Ease the Troubled US-Canadian Relationship? Trump Administration Sues NYC Over Sanctuary City Policy If the moves persist, money managers could be shifting what for decades has been market orthodoxy: that nothing is safer than buying US government debt. But as US fiscal deficits climb, hurt by tax cuts and rising interest costs, the government may look to borrow more, and company debt may be the safer option. In June, money managers pulled $3.9 billion from Treasuries, while adding $10 billion to European and US investment-grade corporate debt, according to EPFR Global data. In July, investors have added another $13 billion to US high-grade corporates, the largest net client purchasing in data going back to 2015, according to a separate note from strategists at Barclays on Friday. Michaël Nizard, a portfolio manager at Edmond de Rothschild Asset Management, started making the switch from government into corporate debt at the end of last year and is holding on to the position. And in a note in the latest week, BlackRock Inc. strategists wrote, 'Credit has become a clear choice for quality.' To the extent this shift is happening, it's a slow change. The US doesn't have foreign currency debt, and can print more dollars as it needs to. When money managers were alarmed about tariff wars in April, US Treasuries still performed better than corporate bonds, even if prices for both sectors broadly fell. And foreign demand for Treasuries has remained resilient, with holdings climbing in May. But tightening corporate bond spreads in recent months may be a function of government debt looking relatively weaker now. The US government lost its last triple A grade in May, when Moody's Ratings cut it to Aa1. The bond rater pointed to factors including the widening deficit and the rising burden of interest, noting that payments will likely absorb around 30% of revenue by 2035, compared with 18% in 2024 and 9% in 2021. And US President Donald Trump's sweeping tax cut bill could add about $3.4 trillion to US deficits over the next decade, according to projections from the nonpartisan Congressional Budget Office. At the same time, corporate profits remain relatively strong, and although there are some early reasons for caution, high-grade companies are generally generating enough earnings to easily pay their interest now. More US companies are topping earnings estimates this reporting season than the same period last year. Valuations for company debt have been high recently, reflecting investor demand for the debt. High-grade US corporate spreads have averaged below 0.8 percentage point, or 80 basis points, in July through Thursday. That's far below the mean for the decade of about 120 basis points, according to Bloomberg index data. Spreads for euro-denominated high-grade corporates have averaged about 85 basis points in July, compared with about 123 basis points for the decade. To some money managers, high valuations for corporate credit are cause to be wary. Gershon Distenfeld, a fund manager at AllianceBernstein Holding LP, pared back a position that favored credit risk to rates risk earlier this month. Dominique Braeuninger, a multi-asset fund manager at Schroders Investment Management Ltd., agrees that corporate bond spreads are too tight to make them attractive. And even if BlackRock is generally positive on corporate debt, it is underweight long-term high-grade notes because spreads are tight, while being overweight short-term credit. But to many market observers, the world appears to be shifting, and it makes sense to hold more corporate debt now. 'What we've seen on the government fiscal side is not great news,' said Jason Simpson, a senior fixed income SPDR ETF strategist at State Street Investment Management. 'Corporates seem to be chugging along nicely.' Week In Review The US leveraged loan market saw more than $83 billion of launches in the latest week, the second busiest on record, including a $7.57 billion two-part deal from Medline that is set to be the market's biggest pricing since 2015. Repricings were an important driver of volume, representing about two thirds of the tranches, as companies look to cut borrowing costs. Many of the loans that were repriced had already been repriced before The return of billion-dollar M&A deals was supposed to be a boon for Wall Street's leveraged finance desks. It's turning out to be anything but, as private equity cuts them out of many of the most coveted deals. Lenders are demanding higher pricing from two European leveraged-loan borrowers, a rare sign of difficulty these days in the buoyant market for sub-investment grade debt. Chinese developer Country Garden Holdings Co. has agreed to some key restructuring terms a group of bank creditors had demanded, potentially easing the path for an overall debt deal. PepsiCo Inc. sold $4.7 billion of bonds in a pair of offerings that included the longest-dated euro-denominated corporate new issue since February. FedEx Corp. followed Pepsi with a rare two-part euro debt sale as some of its existing notes in the single currency near maturity. Meanwhile, General Electric Co. sold $2 billion of investment-grade bonds, as did Lockheed Martin Corp. Saks Global Enterprises launched a debt exchange after weeks of negotiations with creditors as its $600 million fresh financing takes shape. Separately, Walgreens Boots Alliance Inc. launched a multi-currency debt tender. Banks led by UBS Group and Citigroup have offloaded about $2 billion of debt to support Patient Square Capital's acquisition of Patterson Cos., reviving a deal more than three months after the bonds and loans got stuck on their books due to tariff turmoil in the market. Patterson received about $1 billion of orders for the $500 million junk-bond part of the sale. Dog walking service Wag! Group Co. won court permission to try to slash debt and hand control to senior creditor Retriever LLC as early as next month. On the Move Carlyle Group Inc. recruited Alex Chi, who was most recently co-head of Americas private credit at Goldman Sachs Group Inc.'s asset management arm, to lead its direct lending business. Chi will join Carlyle in early 2026. BMO Capital Markets hired Nii Dodoo as head of private credit financing. Dodoo joins from BTIG, where he was a managing director. Christina Chan, BNP Paribas' regional head of loan sales and head of corporate loan syndicate, Asia Pacific, has left the bank. Toronto-Dominion Bank's US credit trading unit has re-hired Sarah Classen from Goldman Sachs Group Inc. for its voice-trading business. Classen starts in mid-September as a director in TD Securities' global US dollar fixed income trading team, based in New York. Ares Management Corp. hired Sarah Cole as a partner and co-head of Ares Global Capital Solutions to bolster its partnerships with banks, insurance companies and across capital markets broadly. Hedge fund Squarepoint Capital LLP recruited Nathan Fabius, a former strategist at Goldman Sachs Group Inc., to cover Latin American debt. Fabius joined Squarepoint this month and is based in New York. Jefferies Financial Group Inc. plans to double the number of people on its credit secondaries team by the end of 2025, as demand has surged from investors who want to buy and sell existing exposure amid a dearth of fresh deals. Ardagh Group SA creditors are set to pay billionaire owner Paul Coulson as much as $300 million as part of a deal to hand over the keys to the company. Burning Man Is Burning Through Cash Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
